In the Spotlight...

Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial

In a phase 1b clinical trial, 12 women with advanced TNBC and 12 with HR-positive breast cancer were treated with entinostat (an HDAC inhibitor) + nivolumab + ipilimumab. Treatment was generally safe ...

Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial

The MIND-DC trial in patients with advanced melanoma showed that adjuvant natural DC (nDC) therapy induced Ag-specific immune responses, but did not provide a survival benefit. Digging deeper, Silva, ...

The gene regulatory basis of bystander activation in CD8+ T cells

Watson et al. investigated “bystander activation”, in which T cells are activated by cytokines rather than TCR stimulation. Single-cell transcriptomics and chromatin accessibility profiling revealed t...

An immunogenetic basis for lung cancer risk

Krishna et al. leveraged genetic and longitudinal clinical data from the FinnGen and UK Biobank, and found that heterozygosity at HLA-II loci is associated with reduced risk of lung cancer in both cur...

Previous Digests

ESMO Targeted Anticancer Therapies Congress 2024

March 6, 2024

The ACIR team attended the ESMO Targeted Anticancer Therapies Congress 2024 in Paris, France. This week’s extensive special feature covers select talks from the conference. We have organized the content by topics below. Keynote lecture on tumor neoantigensYardena Samuels...

MEGA news in gene editing: using new CRISPR technology for RNA knockdown

February 28, 2024

The CRISPR-Cas9 gene editing platform has revolutionized research and medicine by allowing for precise editing of DNA. However, these systems cannot be dynamically regulated and have limitations in their safety and efficacy. To overcome some of these limitations, Tieu...

Taking tips from T cell cancers to improve T cell therapies

February 21, 2024

T cell therapies have been used to treat numerous cancers, but they are often limited by poor proliferation, limited persistence, immunosuppressive tumor environments, and exhaustion. In order to overcome some of these limitations, Garcia and Daniels et al. investigated...

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ed Fritsch

Ute Burkhardt

Ute Burkhardt

Lauren Hitchings

Lauren Hitchings

Gaelle Lespinasse-Llambi

Gaelle Lespinasse-Llambi

Maartje Wouters

Maartje Wouters

Alex Najibi

Alex Najibi

Katherine J. Turner

Katherine J. Turner

Stan Wolf

Stan Wolf

Paula Hochman

Paula Hochman

Shishir Pant

Shishir Pant

Nathan Suek

Nathan Suek

Current Sponsors

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.